Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA
- PMID: 17003087
- DOI: 10.1210/jc.2006-0828
Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA
Abstract
Context: A polymorphism in the human GH receptor gene (d3/fl-GHR) resulting in genomic deletion of exon 3 has been associated with the degree of height increase in response to GH therapy.
Objective: The objective of the study was to evaluate the frequencies of d3/fl-GHR polymorphism genotypes in control and short small-for-gestational-age (SGA) populations.
Design: An adult control population with heights normally distributed (ACPNH) between -2 and +2 sd score (SDS) and a short non-GH-deficient SGA child population were selected.
Setting: Thirty Spanish hospitals participated in the selection of the short non-GH-deficient SGA children in the setting of a controlled, randomized trial, and one of these hospitals selected the ACPNH. CONTROLS AND PATIENTS: Two hundred eighty-nine adult subjects of both sexes constituted the ACPNH and 247 children and adolescents of both sexes the short SGA patients.
Main outcome measures: Heights and weights were recorded in the ACPNH, and auxologic and biochemical data were recorded at each hospital for the SGA patients; d3/fl-GHR genotypes were determined and data analyzed in a single hospital.
Results: In short SGA patients, d3/fl-GHR genotype frequencies were significantly different from those in ACPNH, with a higher frequency of fl/fl genotype (P < 0.0001). In ACPNH, a trend toward diminished d3/d3 genotype frequency was observed in the shortest height group (height <or=-1 SDS and >or=-2 SDS, n = 60).
Conclusions: Our data showed significant differences in the frequency distribution of the d3/fl-GHR genotypes between a normally distributed adult height population and short SGA children, with the biologically less active fl/fl genotype being almost twice as frequent in SGA patients. These data suggest that the d3/fl-GHR polymorphism might be considered among the factors that contribute to the phenotypic expression of growth.
Similar articles
-
The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.J Clin Endocrinol Metab. 2008 Jul;93(7):2709-15. doi: 10.1210/jc.2008-0150. Epub 2008 Apr 29. J Clin Endocrinol Metab. 2008. PMID: 18445665 Clinical Trial.
-
The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients.J Clin Endocrinol Metab. 2006 Sep;91(9):3281-6. doi: 10.1210/jc.2006-0685. Epub 2006 Jun 27. J Clin Endocrinol Metab. 2006. PMID: 16804042 Clinical Trial.
-
Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.J Clin Endocrinol Metab. 2008 Jan;93(1):147-53. doi: 10.1210/jc.2007-1182. Epub 2007 Oct 9. J Clin Endocrinol Metab. 2008. PMID: 17925340
-
Growth hormone receptor polymorphisms.Endocr Dev. 2007;11:28-35. doi: 10.1159/000111055. Endocr Dev. 2007. PMID: 17986824 Review.
-
MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.Eur J Endocrinol. 2017 Dec;177(6):R309-R321. doi: 10.1530/EJE-17-0549. Epub 2017 Sep 13. Eur J Endocrinol. 2017. PMID: 28904008 Review.
Cited by
-
Expression of the growth hormone receptor isoforms and its correlation with the metabolic profile in morbidly obese subjects.Endocrine. 2019 Mar;63(3):573-581. doi: 10.1007/s12020-018-1794-y. Epub 2018 Oct 25. Endocrine. 2019. PMID: 30361972
-
Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly.J Endocrinol Invest. 2020 Feb;43(2):163-171. doi: 10.1007/s40618-019-01096-5. Epub 2019 Aug 7. J Endocrinol Invest. 2020. PMID: 31392573
-
The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.Neuroendocrinology. 2017;105(2):131-140. doi: 10.1159/000448844. Epub 2016 Aug 12. Neuroendocrinology. 2017. PMID: 27513761 Free PMC article.
-
Correlation of fl/d3 polymorphism of growth hormone receptor with the first- and second-year response to recombinant human growth hormone therapy in pre-pubertal Greek children with idiopathic isolated growth hormone deficiency.J Endocrinol Invest. 2011 Sep;34(8):609-14. doi: 10.3275/7267. Epub 2010 Sep 17. J Endocrinol Invest. 2011. PMID: 20855935
-
Disproportionate body lengths correlate with idiopathic-type curvature in the curveback guppy.Spine (Phila Pa 1976). 2010 Mar 1;35(5):511-6. doi: 10.1097/BRS.0b013e3181b52baf. Spine (Phila Pa 1976). 2010. PMID: 20147879 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources